77 related articles for article (PubMed ID: 16741970)
41. Development of a CDK10/CycM
Robert T; Johnson JL; Guichaoua R; Yaron TM; Bach S; Cantley LC; Colas P
Front Chem; 2020; 8():147. PubMed ID: 32175313
[TBL] [Abstract][Full Text] [Related]
42. CDK10 is not a target for aberrant DNA methylation in breast cancer.
Heller G; Ziegler B; Brandstetter A; Novak S; Rudas M; Hennig G; Gehrmann M; Acht T; Zöchbauer-Müller S; Filipits M
Anticancer Res; 2009 Oct; 29(10):3939-44. PubMed ID: 19846932
[TBL] [Abstract][Full Text] [Related]
43. Effects of the cyclin-dependent kinase 10 (CDK10) on the tamoxifen sensitivity of keloid samples.
Liu Y; Xiao Z; Yang D; Ren L; Liu G; Yang L
Molecules; 2012 Feb; 17(2):1307-18. PubMed ID: 22298115
[TBL] [Abstract][Full Text] [Related]
44. Characterization of a novel cardiac isoform of the cell cycle-related kinase that is regulated during heart failure.
Qiu H; Dai H; Jain K; Shah R; Hong C; Pain J; Tian B; Vatner DE; Vatner SF; Depre C
J Biol Chem; 2008 Aug; 283(32):22157-65. PubMed ID: 18508765
[TBL] [Abstract][Full Text] [Related]
45. Low Expression of CDK10 Correlates with Adverse Prognosis in Gastric Carcinoma.
Zhao BW; Chen S; Li YF; Xiang J; Zhou ZW; Peng JS; Chen YB
J Cancer; 2017; 8(15):2907-2914. PubMed ID: 28928881
[No Abstract] [Full Text] [Related]
46. Downregulated CDK10 promotes cancer progression and radioresistance in lung cancer through activating the JNK/c-Jun signaling pathway.
Hong C; Meng Y; Qiu A; Zhang H; Yang L; Hong Y; Huang Y
BMB Rep; 2024 Jun; ():. PubMed ID: 38919013
[TBL] [Abstract][Full Text] [Related]
47. A sib-pair with Al Kaissi syndrome caused by homozygosity for a novel CDK10 splice variant.
Beriwal A; Chauhan L; Kumar A; Dwivedi A
Clin Dysmorphol; 2023 Jan; 32(1):32-35. PubMed ID: 36503922
[No Abstract] [Full Text] [Related]
48. Exercise-Induced miR-210 Promotes Cardiomyocyte Proliferation and Survival and Mediates Exercise-Induced Cardiac Protection against Ischemia/Reperfusion Injury.
Bei Y; Wang H; Liu Y; Su Z; Li X; Zhu Y; Zhang Z; Yin M; Chen C; Li L; Wei M; Meng X; Liang X; Huang Z; Cao RY; Wang L; Li G; Cretoiu D; Xiao J
Research (Wash D C); 2024; 7():0327. PubMed ID: 38410280
[TBL] [Abstract][Full Text] [Related]
49. Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions.
Juric V; Murphy B
Cancer Drug Resist; 2020; 3(1):48-62. PubMed ID: 35582046
[TBL] [Abstract][Full Text] [Related]
50. Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.
Tibes R; Bogenberger JM
Front Oncol; 2019; 9():1205. PubMed ID: 31921615
[TBL] [Abstract][Full Text] [Related]
51. Association of Cyclin Dependent Kinase 10 and Transcription Factor 2 during Human Corneal Epithelial Wound Healing in vitro model.
Zehra M; Mushtaq S; Ghulam Musharraf S; Ghani R; Ahmed N
Sci Rep; 2019 Aug; 9(1):11802. PubMed ID: 31413335
[TBL] [Abstract][Full Text] [Related]
52. The awakening of the CDK10/Cyclin M protein kinase.
Guen VJ; Gamble C; Lees JA; Colas P
Oncotarget; 2017 Jul; 8(30):50174-50186. PubMed ID: 28178678
[TBL] [Abstract][Full Text] [Related]
53. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker SR; Mallinger A; Workman P; Clarke PA
Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
[TBL] [Abstract][Full Text] [Related]
54. Mutant p53 protects ETS2 from non-canonical COP1/DET1 dependent degradation.
Carrero ZI; Kollareddy M; Chauhan KM; Ramakrishnan G; Martinez LA
Oncotarget; 2016 Mar; 7(11):12554-67. PubMed ID: 26871468
[TBL] [Abstract][Full Text] [Related]
55. Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Jia Y; Domenico J; Swasey C; Wang M; Gelfand EW; Lucas JJ
PLoS One; 2014; 9(5):e97448. PubMed ID: 24848372
[TBL] [Abstract][Full Text] [Related]
56. Knockdown of cyclin-dependent kinase 10 (cdk10) gene impairs neural progenitor survival via modulation of raf1a gene expression.
Yeh CW; Kao SH; Cheng YC; Hsu LS
J Biol Chem; 2013 Sep; 288(39):27927-39. PubMed ID: 23902762
[TBL] [Abstract][Full Text] [Related]
57. Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.
Romano G
ISRN Oncol; 2013; 2013():305371. PubMed ID: 23840966
[TBL] [Abstract][Full Text] [Related]
58. Identification of murine cdk10: association with Ets2 transcription factor and effects on the cell cycle.
Bagella L; Giacinti C; Simone C; Giordano A
J Cell Biochem; 2006 Oct; 99(3):978-85. PubMed ID: 16741970
[TBL] [Abstract][Full Text] [Related]
59. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity.
Kasten M; Giordano A
Oncogene; 2001 Apr; 20(15):1832-8. PubMed ID: 11313931
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
